Global STD Diagnostics Market Size By Type (Chlamydia Testing, Gonorrhea Testing), By Location of Test (Laboratory Tests, Point of Care Tests), By Devices Type (Thermal Cyclers – PCR, Point Of Care (PoC) Devices), By End-User (Diagnostics Centers, Government Organizations), By Geography Scope And Forecast

STD Diagnostics Market Size And Forecast

STD Diagnostics Market size was valued at USD 99,844.86 Million in 2022 and is projected to reach USD 176,321.32 Million by 2030, growing at a CAGR of 7.46% from 2024 to 2030. 

The rising prevalence of STDs is the primary driver of the worldwide STD testing industry. The Global STD Diagnostics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global STD Diagnostics Market Executive Summary

A Sexually Transmitted Diseases (STDs) are sexually transmitted infections that are often contracted through intercourse, blood transfusions, the use of unsterilized medication needles, and mother-to-child transmission during delivery or breastfeeding. These diseases don’t have any symptoms and are identified by a variety of tests, such as blood, urine, or fluid samples. It can be done to cure STDs caused on by bacteria with the use of antibiotics and antiviral medications. Some of the instruments used to diagnose the disease include immunochromatographic tests, flow cytometers, and absorbance microplate readers and others.

The standards that society maintains for sexual behavior have changed significantly throughout time. The danger of spreading STDs has increased as a result of this alteration in sexual behavior, prompting more efforts in diagnosis. Also, the prevalence of STDs may be attributed to limited or inadequate sex education programs. There is an increased probability of transmission when people lack the information and abilities necessary to participate in safe sexual behavior.

We're seeing more and more antibiotic-resistant bacteria causing STDs, which is a real worry. That means we need to be extra careful with diagnostics, making sure we catch infections early so people get the right treatment fast. Spreading out testing is key to keeping tabs on these resistant strains and adjusting our approach to treatment. Thankfully, medical tech is changing the game when it comes to diagnosing STDs. It's getting easier to spot infections with faster, more accurate tools like point-of-care tests and nucleic acid amplification tests (NAATs). These tools are a game-changer because they're so effective and accessible, making it much easier for doctors to find and treat these infections.

Global STD Diagnostics Market Attractiveness Analysis

The Global Sexually Transmitted Disease (STD) Diagnosis market is experiencing a scaled level of attractiveness in the North America region. The North America region has a prominent presence and holds the major share of the global market.   North America is anticipated to account for the significant market share of 36.92% by 2030.

North America dominates the global market for the diagnosis of STDs. The US is expected to be the largest market in the North American region because of the vast number of diagnostic firms and the rising awareness of illnesses. 41,655 of the 133,945 cases of syphilis that were recorded in 2020 were in the primary and secondary (P&S) phases of the illness, which are the most transmittable. Due to the increased demand for diagnostic procedures relevant to these conditions, the country’s market is anticipated to grow as STD incidence rises.

Global STD Diagnostics Market Outlook

Okay, so here's the dealthe STD testing market is booming, and rising STD rates are mostly to blame. These infections are spread through the exchange of vaginal fluids and caused by all sorts of nasty things – bacteria, viruses, parasites, you name it. And anyone can get them. We're talking about stuff like syphilis, gonorrhoea, chlamydia, hepatitis B, genital herpes, and HIV/AIDS. Don't forget HPV and Trichomoniasis vaginalis either! The good news is, if you catch something like syphilis, gonorrhoea, chlamydia, or trichomoniasis, you can treat it. But hepatitis B, genital herpes, HIV/AIDS, and HPV-related infections? Not so much. One of the reasons we're seeing more STD diagnoses is thanks to some pretty amazing advancements in molecular diagnostics.

Labs are getting more flexible! New products are hitting the market, letting them add instruments and equipment when they need them. Take Qiagen Inc., for instance—they got the green light from the European Commission in May 2022 to make the Neu-MoDxHSV 1/2 Quant Assay. It's designed to measure and tell the difference between herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2). On the flip side, the lack of good healthcare in developing countries is really holding back the growth of the global STD testing market. In places like Asia, the Middle East, and North Africa, many people just don't have access to the health info and care they need. This is made even worse by not having enough money or people to provide medical treatment, which makes it tough to promote public health and leads to a larger population infected with HIV.

These days, you hear a lot about being proactive with your health, and that includes understanding the importance of getting checked for STDs regularly. Did you know that the World Health Organisation (WHO) estimates that over 311,000 people die from cervical cancer each year because of human papillomavirus (HPV) infection? That's a huge number, and it's why healthcare folks, governments, and charities are really focusing on preventing and controlling STDs. Because of this increased focus, it's a good time for the STD diagnosis industry to grow. Think about itthe National Health Service (NHS) in the United Kingdom and the Centres for Disease Control and Pre-vention (CDC) in the United States have extensive programs to educate people and encourage routine STD screening.

Global STD Diagnostics Market Segmentation Analysis

The Global STD Diagnostics Market is segmented on the basis of Type, Location of Test, Devices Type, End-User, and Geography.

STD Diagnostics Market, By Type

• Chlamydia Testing
• Gonorrhoea Testing
• Syphilis Testing
• Human Papillomavirus (HPV) Testing
• Human Immunodeficiency Viruses (HIV) Testing
• Herpes Simplex Virus (HSV) Testing
• Human papillomavirus (HPV)
• Trichomonas Vaginalis (TV) Testing

To Get a Summarized Market Report By Type-

So, when we look at the market by Type, it's broken down into a few key areasChlamydia Testing, Gonorrhea Testing, Syphilis Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Viruses (HIV) Testing, Herpes Simplex Virus (HSV) Testing, and Trichomonas Vaginalis (TV) Testing. Right now, Chlamydia Testing is leading the pack, grabbing a significant 31.37% of the market in 2022. Experts think it'll keep growing, too, at a rate of around 5.69% each year. A chlamydia test helps us find the bacteria causing this sexually transmitted illness (STI), which often doesn't show any symptoms in either men or women. Typically, these tests use something called nucleic acid amplification tests (NAATs). Think of NAATs as super-sensitive and specific molecular tests that pinpoint the genetic material of the Chlamydia trachomatis bacteria. The cool thing is, we can use all sorts of samples for these tests, like urine, vaginal, penile, or rectal swabs. Since urine samples are pretty easy to get, NAATs are great for screening. Because of this, routine STI checks almost always include chlamydia testing, particularly for those at higher risk, like young, sexually active adults, pregnant women, and people with multiple partners.

STD Diagnostics Market, By Location of Test

• Laboratory Tests
• Point of Care Tests

So, when it comes to where the testing happens, the market's split between Laboratory Tests and Point of Care Tests. And guess what? Labs are still the big dogs, grabbing a whopping 76.26% of the market back in 2022. Experts predict they'll keep growing at a solid clip of 7.19% each year. Now, let's be real, accurate STD diagnosis and treatment really leans on good ol' lab work. There's a bunch of different ways labs find those STDs, each with its own strengths for speed, accuracy, and how well it can pinpoint the problem. For instance, Flow Cytometry is pretty cool because it can check a bunch of things at once, which is super helpful for spotting co-infections. Using Flow Cytometry in research also really helps us understand the immune system's role in STDs. Plus, with PCR, labs can check for multiple nasty bugs in just one test – giving a really complete picture of the infection.

STD Diagnostics Market, By Devices Type

• Thermal Cyclers – PCR
• Lateral Flow Readers Immunochromatographic Assays
• Flow Cytometers
• Enzyme Linked Immunosorbent Assay (ELISA)
• Point Of Care (PoC) Devices
• Phone Chips (Microfluidics + ICT)
• Porta-ble/Bench Top/Rapid Diagnostic Kits
• Others

So, when we look at the different types of devices, the market breaks down into things like Thermal Cyclers (PCR machines), Lateral Flow Readers (for those quick tests), Flow Cytometers, ELISA readers, Point-of-Care gadgets, even Phone Chips that use microfluidics and communication tech! And of course, we have portable and benchtop rapid diagnostic kits and, well, other stuff.
Thermal Cyclers – you know, those PCR machines – they were the big dogs in 2022, grabbing almost 44% of the market! We're expecting them to keep growing at a decent clip, around 6.78% each year. Basically, these Thermal Cyclers (also called PCR machines) use a process called PCR (Polymerase Chain Reaction) to sniff out STDs. They amplify the DNA or RNA of those nasty pathogens, like bacteria and viruses.
PCR works in three stepsdenaturation, annealing, and extension. Thermal cyclers are key for getting the temperature just right for each step. The cool thing is, PCR is super accurate, so it can find even tiny amounts of infection. That's a big deal when you're trying to catch STDs early, because the virus might not be around in huge numbers at first.

STD Diagnostics Market, By End-User

• Hospitals & Clinics
• Diagnostics Centers
• Government Organizations

When we look at who's actually using these services (that's the "End-User" part), the market breaks down into a few main groupsHospitals & Clinics, Diagnostics Centers, and Government Organizations. Right now, Hospitals & Clinics are the biggest piece of the pie, grabbing a whopping 55.77% of the market back in 2022. And they're not slowing down – we're expecting them to keep growing at a rate of about 7.12% each year! Why? Well, on top of diagnosing STDs, hospitals and clinics offer crucial STD-related counseling and educational services. Healthcare providers give advice on staying safe, avoiding infection, and what could happen if you don't get treated. These counseling sessions give patients a safe space to deal with the emotional and psychological challenges that come with living with an STD.

STD Diagnostics Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

To Get a Summarized Market Report By Geography-

When we look at the world map, the Global STD Diagnostics Market can be broken down into regions like North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Right now, North America is the biggest player, grabbing a whopping 38.27% of the market share in 2022. And it's not stopping there! They're expected to keep growing at a rate of 6.93% for the next few years. Why North America? Well, they unfortunately have a high rate of STDs, making the need for diagnosis crucial. Within North America, the United States is predicted to be the dominant market, thanks to a bunch of diagnostic companies and growing awareness. The Centers for Disease Control and Prevention (CDC) even put out a report in April 2022 called “Sexually Transmitted Disease Surveillance, 2020,” highlighting that STDs are still a big problem in the US.

Europe? Yeah, it was the second biggest market back in 2022, and get thisit's expected to keep growing at a rate of 7.25% each year! Seems like people are becoming more aware and educated, and that's really driving the sexually transmitted diseases (STD) diagnostics market. Plus, more education programs and government efforts? That's just gonna boost demand for STD testing even more. Let's face it, STD's are becoming way too common. Luckily, a lot of countries are putting effort into nationwide screening programs to catch them earlier. And the fact that there are better reimbursement policies for STD services makes things easier for patients, which really helps the STD testing market grow.

Key Players

The “Global STD Diagnostics Market” study report will provide valuable insight emphasizing the global market. The major players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, BIOMÉRIEUX, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., QuidelOrtho Corporation, Hologic, Inc., OraSure Technologies, Siemens, Illumina Inc., See-gene Inc., Qiagen, MedMira Inc., and Cepheid. This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

• In February 2022, Lupin Limited, a Mumbai-based Indian Pharmaceutical firm- received approval from the U.S. FDA for the use of its antibiotic Solosec for treating sexually transmitted infections referred to as trichomoniasis and vaginal infection termed as bacterial vaginosis in women.
• In February 2022, Trinity Biotech, a Medical Laboratory Company based in Ireland & specializing in the production and marketing of clinically diagnostic products- has got the approval of the WHO for HIV screening tests.

Company Regional Footprint

The company’s regional section provides geographical presence, regional level reach, or the respective company’s sales network presence. For instance, F. Hoffmann-La Roche Ltd has its presence globally i.e. in North America, Europe, Asia Pacific and RoW. All the companies considered for profiling are reviewed similarly under this section. These sections help us to understand the overall STD Diagnostics Market presence on a global and country level.

Ace Matrix

This section of the report provides an overview of the company evaluation scenario in the STD Diagnostics Market. The company evaluation has been carried out based on the outcomes of the qualitative and quantitative analyses of various factors such as the product portfolios, technological innovations, market presence, revenues of companies, and the opinions of primary respondents.